Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

NCT ID: NCT00540423

Last Updated: 2011-03-30

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2007-09-30
• Study Completion Date: 2008-12-31

Brief Summary

This is a Phase II/III multicenter study comprising of the double-blind, followed by open-label phases to evaluate and compare the efficacy and tolerability of eltrombopag (SB-497115-GR) in chronic ITP patients

Conditions

Chronic Idiopathic Thrombocytopenic Purpura; Purpura, Thrombocytopenic, Idiopathic

Keywords

thrombopoietin,; immunosuppressive therapy,; eltrombopag,; idiopathic thrombocytopenic purpura,; blood platelet,; splenectomy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SB-497115-GR group

Subject will initiate treatment with SB-497115-GR 12.5mg once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR may be adjusted at 12.5mg, 25mg or 50mg.

Group Type: EXPERIMENTAL

SB-497115-GR 12.5mg

Intervention Type: DRUG

SB-497115-GR 12.5mg tablet once a day

SB-497115-GR 25mg

Intervention Type: DRUG

SB-497115-GR 25mg tablet once a day

SB-497115-GR 50 mg

Intervention Type: DRUG

SB-497115-GR 25mg tablet x2 once a day

placebo group

Subject will initiate treatment with SB-497115-GR 12.5mg matching placebo once a day. Based on the subjects platelet count at each visit, the dose of SB-497115-GR 12.5mg matching placebo may be increased to 2 tablet of SB-497115-GR 12.5mg matching placebo.

Group Type: PLACEBO_COMPARATOR

SB-497115-GR 12.5mg matching placebo

Intervention Type: DRUG

SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day

Interventions

SB-497115-GR 12.5mg

SB-497115-GR 12.5mg tablet once a day

Intervention Type: DRUG

SB-497115-GR 25mg

SB-497115-GR 25mg tablet once a day

Intervention Type: DRUG

SB-497115-GR 12.5mg matching placebo

SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day

Intervention Type: DRUG

SB-497115-GR 50 mg

SB-497115-GR 25mg tablet x2 once a day

Intervention Type: DRUG

Other Intervention Names

SB-497115-GR 50mg

Eligibility Criteria

Inclusion Criteria

Subjects eligible for enrollment in the study must meet all of the following criteria.

At Screening (Week -4 or -3)

• Diagnosed with ITP for at least 6 months prior to screening.
• Have a platelet count of <30,000/µL.
• Previously treated refractory or relapsed patients who have failed to achieve a platelet count of >=30,000/µL despite one or more prior therapies (either H. pylori eradication, corticosteroids, splenectomy, danazol or immunosuppressive drugs). (Note: Previous H. pylori eradication must have been completed at least 3 months prior to screening and clearly be ineffective).
• Previous treatment for ITP with splenectomy, rituximab, and cyclophosphamide must have been completed at Week -4 and clearly be ineffective.
• Subjects treated with cyclosporine A, mycophenolate mofetil or danazol must be receiving a dose that has been stable for at least 3 months prior to screening."
• A complete blood count (CBC) within the reference range, with the following exceptions

1. Hemoglobin: females >=9g/dL and males >=10g/dL are eligible for inclusion if hemorrhage is present.

2. Neutrophil count >=1,500/µL (1.5x109/L) is required for inclusion.

• The following clinical chemistries MUST NOT exceed 1.2 times the normal reference range:creatinine, ALT, AST, total bilirubin and alkaline phosphatase.
• Albumin must be within 80 to 120% of normal range.
• Subject is >=20 years old.
• Female subjects must either be:
• of non-childbearing potential (bilateral tubal ligation or post-menopausal), or
• of childbearing potential and have a negative pregnancy test and agree to use contraceptive methods specified in the GSK List of Highly Effective Methods for Avoidance of Pregnancy
• Hospitalization status: No restriction.
• Gender: No restriction.
• Subject has signed and dated written informed consent. At Randomization (Week 0)
• Have a platelet count of <30,000/µL.
• Previous therapy for ITP with immunoglobulins (IVIG and anti-D) and vincristine must have been completed at least 2 weeks prior to randomization and the platelet count must show a clear downward trend after the last treatment with immunoglobulins.
• Subjects treated with corticosteroids or azathioprine must be receiving a dose that has been stable for at least 4 weeks prior to randomization.
• Prolongation of prothrombin time and activated partial thromboplastin time (aPTT) must not exceed 1.2 times the upper limit of the normal range with no history of hypercoagulable state. (Note: These parameters will be measured at screening or at randomization.)
• CBC and clinical chemistries fulfill the same criteria as those at screening.
• Reticulocyte count within the reference range or elevated in case of bleeding. (Note: This parameter will be measured at screening or at randomization.)

Exclusion Criteria

Subjects meeting any of the following criteria must not be enrolled in the study.

At Screening (Week -4 or -3)

• Any severe medical condition (cardiac, hepatic or renal disorder) other than chronic ITP. (Note: ""Severe"" is defined as >=Grade 3 as a rule according to the ""Classification of the Severity of Adverse Experiences (PAB/SD Notification No.80, dated 29 June 1992) (Appendix X).)
• History of suspected or confirmed arterial or venous thrombosis (e.g., myocardial infarction, deep vein thrombosis) within the last 1 year.
• History of drug/alcohol abuse or dependence within 1 year prior to screening.
• Previous treatment with SB-497115-GR.
• Suspected blood disorder other than ITP.
• Suspected platelet aggregation abnormality.
• Suspected cyclic thrombocytopenia
• Current or history of HIV infection or hepatitis B virus or hepatitis C virus infections.
• Current or history of malignancy (Exception: Subjects with a history of completely resected non-melanomatous skin carcinoma or successfully treated in situ carcinoma are eligible).
• Female subjects who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period.
• Subjects who are deemed unsuitable for the study by the investigator (or sub investigator).
• Subjects who are participating in any other clinical trials at present or ones who previously participated in clinical trials and were treated with investigational products within last one month." At Randomization (Week 0)
• Subject wishes to withdraw consent.
• Subject is lost to follow-up.
• Subject has consumed anti-platelet agents (e.g., ticlopidine and aspirin), anticoagulants, or non-steroidal anti-inflammatory drugs (NSAIDs) for 7days prior to the first dose of study medication and will require these medications during the study period.
• Subjects who are deemed unsuitable for the study by the investigator (or sub investigator).

• Minimum Eligible Age: 20 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

GlaxoSmithKline

INDUSTRY

Sponsor Role: lead

Responsible Party

GSK Clinical Disclosure

Principal Investigators

GSK Clinical Trials

Role: STUDY_DIRECTOR

GlaxoSmithKline

Locations

GSK Investigational Site

Gifu, , Japan

GSK Investigational Site

Hiroshima, , Japan

GSK Investigational Site

Ibaraki, , Japan

GSK Investigational Site

Osaka, , Japan

GSK Investigational Site

Osaka, , Japan

GSK Investigational Site

Tochigi, , Japan

GSK Investigational Site

Tokyo, , Japan

Countries

Japan

References

Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, Ninomiya H, Kosugi H, Nomura S, Ozaki K, Ikeda Y, Hattori T, Katsura K, Kanakura Y. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012 May;10(5):799-806. doi: 10.1111/j.1538-7836.2012.04695.x.

Reference Type: DERIVED

PMID: 22409309 (View on PubMed)

Other Identifiers

108109

Identifier Type: -

Identifier Source: org_study_id